Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced its participation in the National Kidney Foundation (NKF) Spring Clinical Meetings 2023, taking place from April 11 to April 15 in Austin, Texas.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced its participation in the National Kidney Foundation (NKF) Spring Clinical Meetings 2023, taking place from April 11 to April 15 in Austin, Texas. During this event, Akebia will present posters focusing on critical research related to kidney disease, highlighting topics such as inpatient admission and mortality rates among Medicare patients with dialysis-dependent chronic kidney disease (CKD) and blood transfusion rates. The company aims to enhance the lives of individuals affected by kidney disease and is committed to showcasing its findings at this prominent clinical forum. Attendees can visit Akebia's booth (#801) to learn more about their initiatives and research findings.
Positive
- Participation in a key industry event enhances visibility among stakeholders.
- Presentation of research may strengthen credibility in the kidney disease sector.
Negative
- None.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was +5.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Abstracts are available online in the SCM22 Abstract and ePoster Gallery.
Akebia posters include:
- Inpatient Admission and Mortality Rates Among Medicare Patients With Dialysis-Dependent CKD and Hyporesponse to ESAs (Poster #179)
- Blood Transfusion and Transplant Rates Among Medicare Patients With Dialysis-Dependent CKD and Hyporesponse to ESAs (Poster #180)
NKF SCM23 attendees can visit the Akebia booth (#801) in the Exhibit Hall.
About
Akebia Therapeutics® is a registered trademark of
Akebia Therapeutics Contact
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-poster-presentations-at-national-kidney-foundation-spring-clinical-meetings-2023-301792282.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.